Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 13 | 2023 | 162 | 4.450 |
Why?
|
| Rhinitis | 12 | 2023 | 143 | 3.870 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 62 | 1.680 |
Why?
|
| Nasal Polyps | 6 | 2023 | 54 | 1.380 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 138 | 1.180 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2022 | 63 | 1.160 |
Why?
|
| Endoscopy | 9 | 2023 | 182 | 1.000 |
Why?
|
| Chronic Disease | 11 | 2023 | 442 | 0.880 |
Why?
|
| Betacoronavirus | 5 | 2020 | 77 | 0.800 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 19 | 0.760 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 91 | 0.760 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 95 | 0.750 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 15 | 0.680 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 192 | 0.620 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 13 | 0.610 |
Why?
|
| Neutrophils | 1 | 2018 | 106 | 0.580 |
Why?
|
| Otolaryngology | 4 | 2021 | 29 | 0.570 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.560 |
Why?
|
| Mucormycosis | 1 | 2017 | 9 | 0.550 |
Why?
|
| Frozen Sections | 1 | 2017 | 13 | 0.550 |
Why?
|
| Aspergillosis | 1 | 2017 | 13 | 0.550 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3612 | 0.550 |
Why?
|
| Nose Neoplasms | 3 | 2022 | 40 | 0.530 |
Why?
|
| Humans | 34 | 2023 | 28462 | 0.530 |
Why?
|
| Middle Aged | 15 | 2023 | 9306 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 35 | 0.360 |
Why?
|
| Adult | 11 | 2023 | 8152 | 0.350 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 29 | 0.340 |
Why?
|
| Simulation Training | 2 | 2020 | 38 | 0.330 |
Why?
|
| Nose | 2 | 2021 | 36 | 0.320 |
Why?
|
| Male | 14 | 2021 | 15367 | 0.290 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 21 | 0.290 |
Why?
|
| Female | 14 | 2021 | 15793 | 0.290 |
Why?
|
| Internship and Residency | 2 | 2021 | 217 | 0.280 |
Why?
|
| Aged | 10 | 2023 | 9339 | 0.250 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 67 | 0.250 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 8 | 0.240 |
Why?
|
| Skull Base | 2 | 2023 | 33 | 0.240 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 992 | 0.230 |
Why?
|
| Inflammation | 3 | 2023 | 288 | 0.220 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 15 | 0.220 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 15 | 0.220 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 47 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 137 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 52 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2021 | 51 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 81 | 0.190 |
Why?
|
| Pandemics | 5 | 2020 | 260 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2021 | 11 | 0.180 |
Why?
|
| Air Pollution | 1 | 2021 | 16 | 0.180 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 61 | 0.180 |
Why?
|
| Professional Role | 1 | 2021 | 36 | 0.180 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 3 | 0.180 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 4 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3619 | 0.180 |
Why?
|
| Melanoma | 1 | 2021 | 60 | 0.180 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 7 | 0.180 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 10 | 0.180 |
Why?
|
| Nasopharynx | 1 | 2020 | 5 | 0.170 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 8 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 16 | 0.170 |
Why?
|
| Child | 2 | 2022 | 1423 | 0.170 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.170 |
Why?
|
| Airway Management | 1 | 2020 | 15 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2020 | 14 | 0.170 |
Why?
|
| Smell | 1 | 2020 | 17 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 306 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2020 | 27 | 0.170 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 22 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 7 | 0.170 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 82 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 30 | 0.170 |
Why?
|
| Sella Turcica | 1 | 2019 | 4 | 0.170 |
Why?
|
| Surgeons | 1 | 2021 | 89 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 151 | 0.170 |
Why?
|
| Surgical Wound | 1 | 2019 | 9 | 0.170 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 29 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 125 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 70 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 772 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 114 | 0.160 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 64 | 0.160 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 371 | 0.150 |
Why?
|
| Phenotype | 1 | 2019 | 308 | 0.150 |
Why?
|
| Fibrosis | 1 | 2018 | 30 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 160 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 130 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 119 | 0.150 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 2 | 0.150 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 2 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 247 | 0.140 |
Why?
|
| Frontal Sinus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 2100 | 0.140 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 45 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 206 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 208 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4904 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 520 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 934 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 227 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 824 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 1810 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 57 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 267 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 372 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 358 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 356 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 941 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 2421 | 0.060 |
Why?
|
| Encephalocele | 1 | 2023 | 25 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 2324 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 34 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 45 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 4 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 23 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 600 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 40 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 31 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 17 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 179 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 20 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 104 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 4 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 49 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 18 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 352 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 19 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 28 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 397 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 32 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 13 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 42 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 42 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 76 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 60 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 55 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 35 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 31 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 52 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 190 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 209 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 311 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 473 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 185 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2018 | 37 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 179 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 726 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 329 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 793 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1497 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 389 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2185 | 0.030 |
Why?
|
Papagiannopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_